Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial ...

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

Researchers have discovered how a particular protein affects the growth and spread of colon cancer in humans. The study not ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...

[31] Activation of this pathway results in the phosphorylation of MAPK, which then phosphorylates other factors and kinases, ultimately regulating cell survival, proliferation, and differentiation.

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Over 50% of melanomas harbor activating V600E mutations in Braf gene (BRAF V600E), an oncogene known to be critical for the proliferation and survival of melanoma cells through activation of the ...

The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant ...

As part of The Wistar Institute's Melanoma Research Center, the Villanueva lab pursues new ways to overcome the challenge of melanoma drug resistance. In this paper, the group took aim at melanomas ...